10.1038/s41408-023-00797-8 - Isatuximab, carfilzomib, and dexameth...

This document has been corrected

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

10.1038/s41408-023-00797-8

Published Online: 2023-05-09

Journal: Blood Cancer Journal•Publisher: Springer Science and Business Media LLC

Authors: Albert Oriol•Chang-Ki Min•France Casca•Gracia Martinez•Ivan Špička•Joseph Mikhael•Kenshi Suzuki•Kihyun Kim•Kwee Yong•Ludek Pour•Marcelo Capra•Marie-Laure Risse•Meletios-Athanasios Dimopoulos•Philippe Moreau•Roman Hajek•Ross Baker•Sandrine Macé•Thierry Facon•Thomas Martin•Xavier Leleu•Youngil Koh

This document has been corrected

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

10.1038/s41408-023-00797-8

Published Online: 2023-05-09

Journal: Blood Cancer Journal

NOW

2023-09-27•Correction

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

10.1038/s41408-023-00923-6

* information provided by CrossRef

2023-09-27•Correction

10.1038/s41408-023-00923-6

* information provided by CrossRef

2023-05-09•Published

2023-09-27•Correction

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

10.1038/s41408-023-00923-6

* information provided by CrossRef

This document has been corrected

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

10.1038/s41408-023-00797-8

Published Online: 2023-05-09

Journal: Blood Cancer Journal•Publisher: Springer Science and Business Media LLC